Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor
Kaitlyn J. Andreano, Jennifer G. Baker, Sunghee Park, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 7, pp. 1395-1405
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Jamie O. Brett, Laura M. Spring, Aditya Bardia, et al.
Breast Cancer Research (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 228
Estrogen Receptor Signaling in the Immune System
Binita Chakraborty, Jovita Byemerwa, Taylor Krebs, et al.
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 117-141
Open Access | Times Cited: 110
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
Muriel Lainé, Sean W. Fanning, Ya-Fang Chang, et al.
Breast Cancer Research (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 61
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role
Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 61
Accelerating drug development in breast cancer: New frontiers for ER inhibition
Emanuela Ferraro, Elaine M. Walsh, Jacqueline J. Tao, et al.
Cancer Treatment Reviews (2022) Vol. 109, pp. 102432-102432
Open Access | Times Cited: 42
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Jun Ma, Jack Junjie Chan, Ching Han Toh, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Senthil Damodaran, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.
Annals of Oncology (2023) Vol. 34, Iss. 12, pp. 1131-1140
Open Access | Times Cited: 25
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
Matthew P. Goetz, N.A. Bagegni, Gerald Batist, et al.
Annals of Oncology (2023) Vol. 34, Iss. 12, pp. 1141-1151
Open Access | Times Cited: 24
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
David J. Hosfield, Sandra Weber, Nan‐Sheng Li, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 31
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Maxwell R. Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 743-761
Closed Access | Times Cited: 7
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies
Govinda R Hancock, Jason Gertz, Rinath Jeselsohn, et al.
Endocrinology (2024) Vol. 165, Iss. 6
Closed Access | Times Cited: 6
Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth
Sandeep Artham, Patrick K. Juras, Aditi Goyal, et al.
Science Advances (2024) Vol. 10, Iss. 39
Open Access | Times Cited: 6
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
Alison Harrod, Chun‐Fui Lai, Isabella Goldsbrough, et al.
Oncogene (2022) Vol. 41, Iss. 44, pp. 4905-4915
Open Access | Times Cited: 19
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer
Matthew P. Goetz, Seth A. Wander, Thomas Bachelot, et al.
Future Oncology (2025), pp. 1-8
Open Access
Next-Generation Endocrine Therapies for Breast Cancer
Donald P. McDonnell, Suzanne E. Wardell, Ching‐yi Chang, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 12, pp. 1383-1388
Open Access | Times Cited: 26
From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target
Madhusoodanan Mottamal, Bo-Rui Kang, Xianyou Peng, et al.
ACS Omega (2021) Vol. 6, Iss. 14, pp. 9334-9343
Open Access | Times Cited: 26
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer
Martina Pagliuca, Marco Donato, Agostina Lagodin D’Amato, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 180, pp. 103861-103861
Open Access | Times Cited: 16
Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Sharvina Ziyeh, Lauren Wong, Reva Basho
Current Oncology Reports (2023) Vol. 25, Iss. 7, pp. 689-698
Closed Access | Times Cited: 10
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Argun Akçakanat, Xiaofeng Zheng, Christian X. Cruz Pico, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 11, pp. 3243-3252
Open Access | Times Cited: 23
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
Jackson Liang, Ellen Ingalla, Xiaosai Yao, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 663
Closed Access | Times Cited: 13
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
Derek Dustin, Guowei Gu, Amanda Beyer, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 1, pp. 191-206
Open Access | Times Cited: 19
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival
Athina Giannoudis, Alexander Sartori, Lee Eastoe, et al.
Breast Cancer Research and Treatment (2021) Vol. 190, Iss. 2, pp. 241-253
Open Access | Times Cited: 13
Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
Diana Lüftner, Michael P. Lux, Tanja Fehm, et al.
Geburtshilfe und Frauenheilkunde (2023) Vol. 83, Iss. 03, pp. 299-309
Open Access | Times Cited: 5
Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Zannel Blanchard, Craig M. Rush, Spencer Arnesen, et al.
Molecular Cancer Research (2023) Vol. 21, Iss. 10, pp. 1023-1036
Open Access | Times Cited: 4
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer
Muriel Lainé, Marianne E. Greene, J.D. Kurleto, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top